Research programme: cystic fibrosis therapies - Topia Life Science
Latest Information Update: 23 Dec 2025
At a glance
- Originator Topia Life Sciences
- Class Antifibrotics
- Mechanism of Action Cytoplasmic and nuclear receptor modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cystic fibrosis
Most Recent Events
- 22 Dec 2025 Research programme: cystic fibrosis therapies - Topia Life Science is available for licensing as of 19 Dec 2025. https://topialifesciences.com/
- 22 Dec 2025 Preclinical trials in Cystic fibrosis in United Kingdom (unspecified route) prior to December 2025 (Topia Life Science pipeline; December 2025)